StageZero to Issue Q4 2022 Financial Results on Friday March 31

Toronto, Ontario–(Newsfile Corp. – March 30, 2023) – StageZero Life Sciences (TSX: SZLS) (“StageZero” or the “Company”) today announced that it will release its fourth quarter and year end 2022 operational results after the market closes on Friday March 31, 2023. StageZero’s Chairman and CEO, James Howard-Tripp, will release a webcast presentation at 7:00am ET on Monday April 3, 2023, reviewing the operational results and discussing business developments.

Analyst and Investor Call

Event Date: Monday April 3, 2023
Time: 7:00 am ET
Webcast Link: https://www.gowebcasting.com/12508

While Management had anticipated an early filing of the Company’s year-end financials, the Company instead will file on time as required.

About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT™).

The Company’s next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company’s patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company’s clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).

StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.

Forward-Looking Statements
This press release contains forward-looking statements identified by words such as “expects”, “will” and similar expressions, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company’s actual events to differ materially from those projected herein. Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

For further information please contact:

Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/160597